Pingyangmycin
| Clinical data | |
|---|---|
| Other names | Bleomycin A5 |
| Pregnancy category |
|
| Routes of administration | intravenous, intra-arterial, intramuscular, intratumoral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | amidase |
| Elimination half-life | 1.3 hours |
| Excretion | renal (25-50%) |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ECHA InfoCard | 100.031.221 |
| Chemical and physical data | |
| Formula | C57H89N19O21S2 |
| Molar mass | 1440.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pingyangmycin (also known as bleomycin A5) is an antitumor glycopeptide antibiotic belonging to the bleomycin family, which is produced by Streptomyces verticillus var. pingyangensis n.sp., a variety of Streptomyces verticillus. It was discovered in 1969 at Pingyang County of Zhejiang Province in China, and was brought into clinical use in 1978.[1]
In China, pingyangmycin has largely superseded bleomycin A2 (commonly known as "bleomycin"), since according to Chinese sources it is more effective, costs less, is easier to get, can treat a larger variety of cancers (such as breast cancer and liver cancer) and causes less lung injury.[2][3] Though pingyangmycin and bleomycin can each cause pulmonary fibrosis, pingyangmycin's most serious side effect - which it does not share with bleomycin - is anaphylactic shock, which is rare, but may happen even in a low dose, and can be fatal.[4] In addition, it causes a higher incidence of fever than bleomycin; the occurrence of this complication in patients is between 20 and 50%.
References
- ^ Lin FT, Li DD, Yang XP, Li Q, Xue YC, Zhen YS (1979). "[Antitumor activity and preclinical pharmacologic evaluation of pingyangmycin (author's transl)]". Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 1 (3): 161–6. PMID 95444.
- ^ Zheng JW, Yang XJ, Wang YA, He Y, Ye WM, Zhang ZY (October 2009). "Intralesional injection of Pingyangmycin for vascular malformations in oral and maxillofacial regions: an evaluation of 297 consecutive patients". Oral Oncology. 45 (10): 872–6. doi:10.1016/j.oraloncology.2009.02.011. PMID 19628423.
- ^ Xu HZ, Zhang HY (October 1980). "[The isolation and identification of pingyangmycin (author's transl)]". Yao Xue Xue Bao = Acta Pharmaceutica Sinica. 15 (10): 609–14. PMID 6167140.
- ^ Shou BQ, Mao Z, Zhang SL, Yang Z (October 2009). "[Allergy caused by minidose and low concentration Pingyangmycin: a case report]". Hua Xi Kou Qiang Yi Xue Za Zhi = Huaxi Kouqiang Yixue Zazhi = West China Journal of Stomatology. 27 (5): 572–3. PMID 19927737.
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.